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Abstract
 
Epstein-Barr virus (EBV) latent membrane protein (LMP)2 is a multiple membrane spanning
molecule which lacks ectodomains projecting into the lumen of the endoplasmic reticulum
(ER). Human CD8
 
 
 
 cytotoxic T lymphocytes (CTL)s recognize a number of epitopes within
LMP2. Assays with epitope-specific CTLs in two different cell backgrounds lacking the trans-
porter associated with antigen processing (TAP) consistently show that some, but not all,
LMP2 epitopes are presented in a TAP-independent manner. However, unlike published ex-
amples of TAP-independent processing from endogenously expressed antigens, presentation of
TAP-independent LMP2 epitopes was abrogated by inhibition of proteasomal activity. We
found a clear correlation between hydrophobicity of the LMP2 epitope sequence and TAP in-
dependence, and experiments with vaccinia minigene constructs expressing cytosolic epitope
peptides confirmed that these more hydrophobic peptides were selectively able to access the
HLA class I pathway in TAP-negative cells. Furthermore, the TAP-independent phenotype of
particular epitope sequences did not require membrane location of the source antigen since (i)
TAP-independent LMP2 epitopes inserted into an EBV nuclear antigen and (ii) hydrophobic
epitope sequences native to EBV nuclear antigens were both presented in TAP-negative cells.
We infer that there is a proteasome-dependent, TAP-independent pathway of antigen presen-
tation which hydrophobic epitopes can selectively access.
Key words: MHC class I presentation • CD8
 
 
 
 epitopes • hydrophobicity • Epstein-Barr virus • 
TAP independence
 
Introduction
 
CD8
 
 
 
 CTL recognition of target cells requires the presen-
tation of peptide epitopes on the cell surface in the context
of MHC class I molecules (1). In the great majority of
cases, these epitopes are generated from endogenously ex-
 
pressed proteins by breakdown in the cytosol via a
large multicatalytic protease complex, the proteasome (2).
Thereafter, the resultant peptides are pumped from the
 
cytosol into the endoplasmic reticulum (ER)
 
*
 
 by the
transporter associated with antigen processing (TAP), a
heterodimeric complex composed of TAP1 and TAP2
subunits whose function is ATP dependent (3–5). Of the
many peptides transported in this way, a small number are
selected by virtue of their ability to bind with high affinity
to the peptide-binding grooves of nascent MHC class I
molecules, thereby stabilizing the MHC class I–
 
 
 
2-micro-
globulin–peptide complex and allowing its subsequent
transport to the cell surface (6, 7). Importantly, this is the
major route of antigen processing not just for cytosolic pro-
teins but also for membrane/secretory proteins which natu-
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rally access the ER but can be returned to the cytosol by
retrograde transport (8) and there targeted for processing by
the conventional TAP-dependent, proteasome-dependent
route (9–13).
Nevertheless, in cells lacking a functional TAP trans-
porter, of which the best example is the human T2 cell line
where both TAP1 and TAP2 genes are deleted (14), some
MHC–peptide complexes are still presented at the cell sur-
face (15, 16). In this context, a number of possible mecha-
nisms have been identified for the TAP-independent
presentation of antigenic peptides from endogenously ex-
pressed proteins. The best known example involves pep-
tides derived from signal sequences of membrane/secretory
proteins (10, 15, 16); signal sequences target such proteins
to the Sec61 translocon and, after protein translocation, are
naturally liberated in the ER by the action of the signal
peptidase enzyme. A second example involves certain
epitopes located within the ectodomains of transmembrane
proteins which, rather than being generated in the conven-
tional way after retrograde transport to the cytosol, appear
to be liberated within the lumen of the ER by as yet poorly
defined ER proteases (17–19). Thirdly, there is at least one
example of a naturally secreted viral protein from which an
epitope is generated by the trans-Golgi-resident protease
furin (20). Note that in all the above cases the pathway of
epitope presentation is not only TAP independent but also
proteasome independent.
In earlier work, we (21) and others (22) have reported
TAP-independent processing of an Epstein-Barr virus
(EBV)-coded antigen, the latent membrane protein (LMP)2,
in the T2 cell background in vitro. Furthermore, CD8
 
 
 
CTL responses to LMP2 have been identified within a
TAP-deficient individual (23), and, if such responses are
indeed induced by direct priming, their existence would
suggest functionality of this TAP-independent pathway in
vivo. LMP2 is an integral membrane protein with short cy-
tosolic NH
 
2
 
- and COOH-terminal domains flanking 12
tandemly arranged transmembrane domains that are joined
by tight loops showing minimal projection into the ER
(24, 25). Of four CTL epitopes identified within LMP2,
three lying within transmembrane sequences were pre-
sented in the TAP-negative T2 cell line, whereas a fourth
epitope located on a cytosolic loop was not (21, 22). Ex-
tending this work to other epitopes within LMP2 and then
to epitopes in EBV nuclear antigens, we present evidence
for a novel pathway of TAP-independent presentation
which does not require membrane location of the source
antigen, is proteasome-dependent and selectively involves
hydrophobic epitope sequences.
 
Materials and Methods
 
Cell Lines.
 
Standard EBV-transformed lymphoblastoid cell
lines (LCLs), the EMO LCL derived from a patient with a ho-
mozygous mutation in the TAP2 allele (23), the TAP1/TAP2-
negative T2 cell line (14), and T2 cells stably transfected either
with rat TAP1 and TAP2 alleles (designated T3 cells; reference
26) or with the HLA B
 
*
 
2704 (T2:B27.04) or HLA B
 
*
 
3501 (T2:
 
B35.01) alleles (27, 28) were maintained in RPMI 1640 contain-
ing 10% FCS, 2 mM 
 
L
 
-glutamine, 100 U/ml penicillin, and 100
 
 
 
g/ml streptomycin (growth medium). A human papilloma virus
negative cervical carcinoma cell line, C-33 A (ATCC HBT-31;
HLA type A2, B7, B44), and a SV40-immortalized human kera-
tinocyte (SVK) line (HLA type A2, A29, B8, B40) were main-
tained in DME medium supplemented as above.
 
Peptides.
 
Synthetic peptides were synthesized by standard flu-
orenyl-methoxycarbonyl chemistry (Alta Bioscience) and dis-
solved in DMSO, and their concentration determined by biuret
assay
 
.
CTL Clones.
 
EBV-specific CTL clones were generated from
virus-immune donors by autologous LCL stimulation as de-
scribed previously (29, 30), and mapped to the following
epitopes: HLA A
 
*
 
0201-restricted epitopes, CLGGLLTMV
(CLG) and LLWTLVVLL (LLW); the HLA B
 
*
 
4001-restricted
epitope, IEDPPFNSL (IED); the HLA B
 
*
 
2704-restricted
epitope, RRRWRRLTV (RRR); and the HLA A
 
*
 
2402-
restricted epitope, TYGPVFMCL (TYG) all from LMP2; the
HLA-B
 
*
 
3501-restricted epitope, HPVGEADYFEY (HPV) from
EBNA1; the HLA B
 
*
 
3501-restricted epitope, YPLHEQHGM
(YPL) from EBNA3A; the HLA B
 
*
 
2705-restricted epitope,
HRCQAIRKK (HRC) from EBNA3B; the HLA B
 
*
 
2705-
restricted epitope, FRKAQIQGL (FRK) from EBNA3C; the
HLA A
 
*
 
0201-restricted epitopes, GLCTLVAML (GLC) from
BMLF1, TLDYKPLSV (TLD) from BMRF1; and YVLDHLIVV
(YVL) from BRLF1 (references 31 and 32, data not shown). The
LMP2-specific HLA-B63 restricted CTL clone EFA c8.24 has
been described previously (23).
 
Cytotoxicity Assays.
 
Chromium release assays on target cells
infected overnight with recombinant vaccinia viruses (multiplic-
ity of infection [moi] of 10 unless otherwise indicated) were car-
ried out as described previously (29). Peptide-loaded targets were
exposed immediately before the assay (during the last hour of
Chromium labeling) to the epitope peptide at a final concentra-
tion of 2 
 
  
 
10
 
 
 
8
 
 M unless otherwise stated or to an equivalent
amount of DMSO solvent as a control. For assays of proteasome
dependence, C-33 A or SVK cells were first incubated for 1 h in
the presence of 100 
 
 
 
M lactacystin (provided by E.J. Corey, Har-
vard University, Boston, MA; reference 33) or of 1 
 
 
 
M epoxo-
micin (34) before recombinant vaccinia virus infection and the
infected target cells incubated overnight in fresh medium before
being used in a standard 5-h chromium release assay.
 
Construction of Recombinant Vaccinia Viruses.
 
Unless otherwise
stated, recombinant vaccinia viruses were generated using estab-
lished protocols based on homologous recombination and selec-
tion of TK-recombinant viruses using the pSC11 transfer plas-
mids (35). The HLA A
 
*
 
2402, B
 
*
 
2704, and B
 
*
 
4001 cDNAs were
blunt-end cloned into the Sma1 cloning site pSC11, before con-
struction of the recombinant vaccinia viruses vA24, vB27, and
vB40. The vaccinia viruses expressing the EBV antigens LMP2
(vLMP2), EBNA1 lacking the glycine-alanine repeat (vE1dGA),
EBNA3A (vEBNA3A), EBNA3B (vEBNA3B), EBNA3C
(vEBNA3C), BMLF1 (vBMLF1), BMRF1 (vBMRF1), BRLF1
(vBRLF1), the HLA B
 
*
 
3501 heavy chain (vB35), and control virus
vTK-have been described previously (29, 36)
 
Chimaeric Constructs.
 
Construction of BMLF1 mutants con-
taining LMP2-derived peptide epitopes was carried out using the
plasmid pBMLF1 (36) as follows. The LMP2 peptide epitopes
CLG and TYG were inserted separately into the coding sequence
of BMLF1 at the Nco1 site (corresponding to amino acid position
93) generating pBMLF1-CLG-N and pBMLF1-TYG-N, or at
the EcoR1 site (corresponding to BMLF1 amino acid position 
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379) generating pBMLF1-CLG-E and pBMLF1-TYG-E. Inser-
tion of LMP2 epitopes was achieved by annealing overlapping
oligonucleotides encoding each epitope, followed by ligation of
the annealed products with pBMLF1 linearized with either Nco1
or EcoR1. For insertion of epitopes into the Nco1 site the fol-
lowing oligonucleotides were used: for the CLG epitope, 5
 
 
 
-
CATGCATGCCTCGGTGGCCTGCTCACCATGGTA-3
 
  
 
and
5
 
 
 
-CATGTACCATCGTGAGCAGGCCACCGAGGCATG-3
 
 
 
;
and for the TYG epitope, 5
 
 
 
-CATGCAACATACGGTCCAG-
TTTTTATGTGCCTC-3
 
 
 
 and 5
 
 
 
-CATGGAGGCACATAAA-
AACTGGACCGTATGTTG-3
 
 
 
. For insertion of epitopes into
the EcoR1 site the following oligonucleotides were used: for the
CLG epitope, 5
 
 
 
-AATTTATGTGCCTCGGTGGCCTGCTC-
ACCATGGTAGCCC-3
 
  
 
and 5
 
 
 
-AATTGGGCTACCATGG-
TGAGCAGGCCACCGAGGAACATA-3
 
 
 
; and for the TYG
epitope, 5
 
 
 
-AATTAAGAACATACGGTCCAGTTTTTATGT-
GCCTCGCTC-3
 
 
 
 and 5
 
 
 
-AATTGACCGAGGCACATAAAA-
ACAGGTCCGTATGTTCTT-3
 
 
 
.
All constructs were sequenced to confirm correct in frame in-
sertion of the LMP2 epitopes into BMLF1. The coding se-
quences for BMLF1 and BMLF1 epitope chimaeras were then
excised by digestion with Xba1 and HindIII, and ligated into the
vaccinia transfer vector pRB21 (37) which had been digested
with Nhe1 and HindIII. The recombinant vaccinia viruses
vBMLF1, vBMLF1-CLG-N, vBMLF1-CLG-E, vBMLF1-TYG-N,
and vBMLF1-TYG-E were generated using standard methods based
on restoration of wild-type plaque phenotype.
 
Minigene Constructs.
 
Expression of minimal epitopes from
vaccinia viruses was achieved by cloning synthetic minigenes
coding for the LMP2 epitopes CLG, TYG, IED, RRR, the
EBNA3A epitope YPL, the BMLF1 epitope GLC, and the
BMRF1 epitope TLD into the vaccinia transfer vector
pSC11.30R.2 (19). Peptide epitopes were inserted into the
Nco1/BglII cut vector by annealing overlapping oligonucleotides
coding for the appropriate epitope sequences as follows: CLG
sense 5
 
 
 
-CATGTGCCTCGGTGGCCTGCTCACCATGGT-
ATAATTAATTAAG-3
 
 
 
 and antisense 5
 
 
 
-GATCCTTAATTA-
ATTATACCATGGTGAGCAGGCCACCGAGGCA-3
 
 
 
; TYG
sense 5
 
 
 
-CATGACATACGGTCCAGTTTTTATGTGCCTC-
TAATTAATTAAG-3
 
  
 
and antisense 5
 
 
 
-GATCCTTAATT-
AATTAGAGGCACATAAAAACTGGACCGTATGT-3
 
 
 
; IED
sense 5
 
 
 
-CATGATTGAGGACCCACCTTTTAATTCTCTT-
TAATTAATTAAG-3
 
 
 
 and antisense 5
 
 
 
-GATCCTTAATTAA-
TTAAAGAGAATTAAAAGGTGGGTCCTCAAT-3
 
 
 
; RRRW
sense 5
 
 
 
-CATGAGAAGATGGCGCCGTTTGACTGTTTAA-
TTAATTAAG-3
 
 
 
 and antisense 5
 
 
 
-GATCCTTAATTAATTA-
AACAGTCAAACGGCGCCATCTCCTTCT-3
 
 
 
; YPL sense
5
 
 
 
-CATGTACCCATTACATGAACAACACGGCATGTAA-
TTAATTAAG-3
 
  
 
and antisense 5
 
 
 
-GATCCTTAATTAATTA-
CATGCCGTGTTGTTCATGTAATGGGTA-3
 
 
 
; GLC sense
5
 
 
 
-CATGGGGCTCTGCACCCTGGTGGCCATGCTATA-
ATTAATTAAG-3
 
  
 
and antisense 5
 
 
 
-GATCCTTAATTAAT-
TATAGCATGGCCACCAGGGTGCAGAGCCC-3
 
 
 
; TLD sense
5
 
 
 
-CATGACCCTAGACTACAAGCCTCTGAGTGTGTAA-
TTAATTAAG-3
 
 
 
; and antisense 5
 
 
 
-GATCCTTAATTAATTA-
CACACTCAGAGGCTTGTAGTCTAGGGT-3
 
 
 
.
In addition, another vaccinia recombinant vL
 
 
 
CLG express-
ing an ER-targeted form of the CLG epitope was constructed by
cloning the above CLG oligonucleotide minigene sequence into
the vaccinia transfer vector pSC11L
 
 
 
 (19). This recombinant en-
codes a 26-mer peptide composed of the influenza haemaggluti-
nin HA-1 leader sequence MKANLLVLLCALAAADA followed
by the CLG epitope. The integrity of all minigene constructs was
 
checked by sequencing before construction of recombinant vac-
cinia viruses as described previously (35).
 
Immunoblotting and Immunofluorescence.
 
For immunoblotting,
protein extracts were resolved by SDS-PAGE (10% gel), trans-
ferred to nitrocellulose, and probed with specific antibodies fol-
lowed by detection using a chemiluminescence protocol (Amer-
sham Pharmacia Biotech). LMP2 was detected using the rat
monoclonal antibody 14B7 (38), human TAP1/TAP2 using rab-
bit antisera (39), actin using a monoclonal antibody (Sigma-Aldrich),
and BMLF1 using rabbit antiserum 
 
 
 
SM53 (40). For immunoflu-
orescence assays of LMP2 and BMLF1 expression, cell smears
were fixed in 1% paraformaldehyde and stained using the above
reagents followed by an appropriate second step antibody.
 
Results
 
Presentation of B
 
*
 
4001- and B
 
*
 
2704-restricted Epitopes from
LMP2 Is TAP Dependent.
 
Fig. 1 illustrates the topology
of the multiple membrane spanning LMP2 protein and
identifies eight CD8
 
 
 
 CTL epitopes, either previously
known or defined in this study, plus their HLA restriction
alleles. Earlier work has classified three epitopes lying
within transmembrane sequences (CLG/A
 
*
 
0201, LLW/
A
 
*
 
0201, and PYL/A
 
*
 
23) as TAP independent and one
epitope situated on a cytosolic loop (SSC/A
 
*
 
1101) as TAP
dependent (21, 22). To extend this analysis to other
epitopes, we first carried out chromium release assays in
the TAP-negative T2 cell line, expressing LMP2 in these
cells via a recombinant vaccinia virus and where necessary
providing the appropriate HLA allele through a second
vaccinia construct.
In the first set of assays, we analyzed processing of the
B
 
*
 
2704-restricted epitope RRRWRRLTV (LMP2 aa
236–244) which lies on a cytosolic loop of the protein in its
native orientation in the membrane. As shown in Fig. 2 A,
there was clearly no specific recognition of T2 target cells
coinfected with a vaccinia virus expressing HLA B
 
*
 
2704
(vB27) and a vaccinia virus expressing LMP2 (vLMP2),
whereas T2 cells infected with vB27 and pulsed with the
RRR epitope peptide were efficiently lysed. As a control
target in these assays we included the T3 cell line which
was derived from T2 by stable transfection with the rat
TAP1 and TAP2 cDNAs (26). Importantly, when T3 cells
were coinfected with vB27 and vLMP2, there was signifi-
cant recognition of LMP2 by RRR-specific CTLs, con-
firming that presentation of the RRR epitope was indeed
TAP dependent. In this case we were also able to test T2:
B27.04 cells (a HLA B
 
*
 
2704 stable transfectant of T2; ref-
erence 27) and again found that these cells were unable to
present the RRR epitope when infected with vLMP2 but
were well recognized after peptide loading (data not
shown). Then we carried out a similar set of assays using
CTL clones specific for the HLA B
 
*
 
4001-restricted epitope
IEDPPFNSL (LMP2 amino acid [aa] 200–208), which in
contrast to the RRR epitope, lies on a lumenal loop of the
protein (Fig. 1). Interestingly, this epitope also proved to
be TAP dependent. Thus, as shown in Fig. 2 B, there was
no specific lysis of T2 cells coinfected with vB40 and 
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Figure 1. Diagrammatic representation of the
LMP2 molecule in its native orientation in the
membrane. The positions of CD8  T cell epitope
sequences are shown; epitopes are identified by the
first three letters of their amino acid sequence and
by their HLA class I restricting alleles.
Figure 2. Definition of LMP2 epitopes as
TAP dependent or TAP independent. Data
from cytotoxicity assays using CTL clones
specific for (A) RRR/B27, (B) IED/B40,
(C) TYG/A24, and (D) CLG/A2 as effec-
tors and either T2 cells (TAP-negative) or
T3 cells (TAP1/TAP2-transfectant of T2) as
targets. Target cells were infected with a
vaccinia recombinant–expressing LMP2
(vLMP2) and, where necessary, with a re-
combinant expressing the relevant HLA
class I restriction element (vB27, vB40,
vA24) either alone or in combination with
vLMP2. In the case of T2 cell assays, target
cells (where necessary infected with vB27,
vB40, or vA24) were preexposed to the
epitope peptide as a positive control or to an
equivalent concentration of DMSO solvent
as a negative control. vTK  is a control
vaccinia recombinant. Results are shown as
percentage of specific lysis in standard 5-h
chromium release assays using effector:target
ratios of 5:1 (black bar) and 2:1 (shaded bar). 
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vLMP2 (vB40/vLMP2), whereas T3 cells coinfected with
both viruses or T2 cells infected with vB40 and pulsed with
the IED epitope peptide were well recognized.
 
Presentation of the A
 
*
 
2402-restricted Epitope from LMP2 Is
TAP Independent.
 
Next, we extended this analysis to
look at the HLA A
 
*
 
2402-restricted epitope, TYG-
PVFMCL (LMP2 aa 419–427), predicted to be located
partially within a cytosolic loop and a transmembrane sec-
tion (Fig. 1). Fig. 2 C shows a representative result from
chromium release assays using CTL clones specific for this
epitope, again using a vaccinia vector vA24 to express the
HLA restriction allele in T2 cells and coinfecting with
vLMP2 (vA24/vLMP2). In this case, we did observe sig-
nificant recognition of coinfected target cells by epitope-
specific CTLs, at levels equivalent to that seen with
epitope-peptide loading (vA24/peptide). Indeed, levels of
lysis of these target cells were similar to those seen follow-
ing vA24/vLMP2 coinfection of the TAP-positive T3 cell
line. For reference, Fig. 2 D shows the corresponding set
of results obtained using CTLs specific for the A
 
*
 
0201-
restricted epitope CLGGLLTMV (LMP2 aa 426–434),
previously shown to be TAP independent (21). Here in-
fection of T2 cells (naturally expressing HLA A
 
*
 
0201)
with vLMP2 was sufficient to induce lysis to levels ap-
proaching those seen for CLG epitope-loaded target cells.
Note that CLG-specific clones also show significant base-
line lysis of the T2 cell line itself, reflecting the fact that
these cells are naturally EBV-positive and expressing low
levels of LMP2 endogenously.
 
Mapping of a TAP-independent, HLA B63-restricted Epitope
in LMP2. In a previous report studying individuals with
deficiencies in peptide transport due to a TAP2 mutation,
de la Salle et al. identified a CD8  CTL clone, restricted
through HLA B63, and specific for the EBV LMP2 protein
(23). Here we confirmed that this clone recognizes a TAP-
independent epitope and went on to identify the minimal
epitope sequence. As illustrated in Fig. 3 A the CTL clone
from the TAP2-deficient donor EFA (EFA c8.24) shows
strong lysis of EMO LCL target cells (derived from a HLA-
identical sibling with the same TAP2 mutation) when
LMP2 is overexpressed in these cells from a recombinant
vaccinia virus (vLMP2). Here again, there is lower but still
significant baseline recognition of the EMO LCL itself, re-
flecting low level expression of LMP2 from the endoge-
nous EBV genome, whereas there was no recognition of a
HLA-mismatched LCL target (allo LCL) with or without
vLMP2 infection (Fig. 3 A). Parallel assays using CTLs spe-
cific for known TAP-dependent epitopes confirmed that
the EMO-LCL was indeed operationally TAP-deficient
(data not shown).
Subsequently, we mapped the minimal epitope recog-
nized by CTL clone EFA c8.24. Initial screening of LMP2
peptide panels (30) identified one 14-mer peptide (FLLM-
LLWTLVVLLI, aa 325–338) which mediated rapid T cell–
T cell lysis in a visual assay (data not shown). Limiting dilu-
tions of this 14-mer peptide, and of smaller peptides from
within this region of LMP2, were then assayed for their
ability to enhance lysis of the EMO LCL by EFA c8.24 ef-
fectors. As shown in Fig. 3 B, significant enhancement was
observed with the original 14-mer peptide and also with
the constituent 9-mer aa 330–338 and 8-mer aa 331–338
peptides, whereas other sequences were recognized poorly
if at all. The predicted minimal epitope is therefore the
8-mer WTLVVLLI, which accords well with the proposed
HLA B*63 binding-motif with a threonine at position 2
and isoleucine at the COOH terminus (41). This TAP-
independent HLA B*63-restricted epitope lies within a
predicted transmembrane region of LMP2 and overlaps an-
Figure 3. Mapping of the HLA B*63-restricted,  TAP-independent
WTL epitope within LMP2. (A) CTL clone EFA c8.24 derived from a pa-
tient with a TAP2-inactivating mutation was assayed against the EMO-LCL
derived from an HLA-identical sibling with the same TAP2 mutation and
against an HLA-mismatched standard LCL (Allo LCL). Targets were used
without vaccinia infection (cont) or after infection with vTK  or with
vLMP2. Results are expressed as in Fig. 2 using effector:target ratios of
5:1 (black bar) and 1:1 (shaded bar). (B) Results of a cytotoxicity assay us-
ing CTL clone EF c8.24 as effectors and the EMO-LCL as a target. Tar-
get cells were preexposed to 10-fold dilutions of peptides (10 5–10 11M)
representing the indicated residues within the LMP2 325–340 region
(330-338,   331-338,   325-338,   329-337,   332–340) or to DMSO
as a control ( ). The minimal epitope mediating optimal recognition was
WTLVVLLI, LMP2 331–338.1058 Proteasome-dependent, TAP-independent Processing
other previously characterized TAP-independent epitope
LLW/A2 (Fig. 1).
TAP-independent Presentation of LMP2 Epitopes in an Epi-
thelial Cell Background. We were interested to see if the
TAP-independent presentation of LMP2 epitopes observed
in T2 cells could be reproduced in a different TAP-nega-
tive cell background. For this purpose we used C-33A, a
human cervical carcinoma cell line, which in preliminary
work was found to be deficient for presentation of standard
TAP-dependent HLA class I epitopes. As shown by the
immunoblots in Fig. 4 A, we analyzed the C-33A cell line
for TAP expression and found that TAP1 was absent and
TAP2 was barely detectable whereas both proteins were
strongly expressed in the SVK cell line and in a standard
LCL. Processing of LMP2 epitopes for CTL recognition
was then investigated using C-33A cells as targets, again
where necessary providing the appropriate HLA allele via a
recombinant vaccinia virus. Representative results from
such chromium release assays are shown in Fig. 4 B–D.
Using CTLs specific for the IED/B40 TAP-dependent
epitope, there was no significant lysis of C-33A cells coin-
fected with vLMP2 and vB40 above that seen with vTK-/
vB40 coinfected control targets, whereas vB40-infected
targets pulsed with the IED epitope peptide were well rec-
ognized (Fig. 4 B). This same pattern of results was also ob-
served in parallel assays using CTLs specific for the RRR/
B27 TAP-dependent epitope (data not shown). However,
when C-33A cells (naturally HLA A*0201-positive) were
infected with vLMP2 alone and used in chromium release
assay with CTL effectors specific for the TAP-independent
CLG/A2 epitope, there was significant lysis above that of
the control targets (Fig. 4 C). Likewise when infecting
C-33A cells with vLMP2 and coinfecting with vA24, there
was clear recognition of the TAP-independent TYG/A24
epitope by epitope-specific CTLs (Fig. 4 D). By contrast,
all four LMP2 epitopes described above were efficiently
processed and presented in parallel assays conducted in the
TAP-positive SVK cell line (data not shown). Thus, assays
in epithelial cell backgrounds produced the same character-
ization of LMP2 epitopes as either TAP-dependent or
TAP-independent as had the assays in T2 cells.
Presentation of LMP2 CTL Epitopes Is Blocked by Protea-
some Inhibitors. The same epithelial lines were then used
in experiments where, before infection with vLMP2 and
Figure 4. Results of assays conducted in
the C-33A epithelial cell line. (A) Protein
extracts from C-33A cells were compared
with extracts from the TAP1/TAP2-nega-
tive T2 cell line, from a standard TAP-posi-
tive LCL, and from the TAP-positive SVK
epithelial cell line in immunoblots probed
with antisera to TAP1, TAP2, and actin.
Note that the anti-TAP1 antisera also cross-
reacts with a nonspecific protein running
below TAP1 in the gel. (B) Results of a cy-
totoxicity assay using as effectors an IED/
B40-specific CTL clone and as targets C-33A
cells uniformly infected with vB40 and addi-
tionally either coinfected with vTK- or
vLMP2 or pre-exposed to IED epitope
peptide or to DMSO solvent as a control.
(C) Results of a similar cytotoxicity assay
using a CLG/A2-specific CTL clone as ef-
fectors. (D) Results of a similar assay using a
TYG/A24-specific CTL clone as effectors
and vA24 to provide the HLA restriction el-
ement. Results are expressed as in Fig. 2 us-
ing effector:target ratios of 8:1 (black bar)
and 4:1 (shaded bar).1059 Lautscham et al.
where necessary with a vaccinia expressing the appropriate
HLA restriction element, the cells were briefly pre-pulsed
with the proteasome-specific inhibitor lactacystin (33). Fig.
5 A illustrates data from experiments in the TAP-positive
SVK cell-line (naturally expressing A*0201 and B*4001)
which show that two TAP-dependent epitopes, RRR/
B27 and IED/B40, were presented efficiently from vac-
cinia-expressed LMP2 in the absence of lactacystin, but
presentation of both epitopes was blocked when SVK cells
were pretreated with the inhibitor. However, importantly,
such lactacystin-treated cells clearly did show specific lysis if
loaded with the epitope-peptide. In addition, lactacystin
treatment itself did not affect vectored expression of LMP2
in these assays; equivalent levels of the protein were de-
tected in treated and untreated cells by immunofluores-
cence staining as well as by immunoblot analysis with
LMP2-specific antibodies (data not shown).
Fig. 5 B presents similar experiments conducted in SVK
target cells now using CTLs specific for the TAP-indepen-
dent HLA A*0201-restricted CLG and LLW epitopes from
LMP2. These results clearly show that presentation of the
TAP-independent epitopes was also blocked by pretreat-
ment of SVK targets with lactacystin, whereas peptide
loading of lactacystin-treated target cells allowed CTL rec-
ognition. These experiments were then extended to the
TAP-negative C-33A cell line, this time analyzing presen-
tation of the TAP-independent epitopes CLG/A2 and
TYG/A24 (Fig. 5 C). Although both of these epitopes
Figure 5. Lactacystin inhibition of the presentation of
LMP2 epitopes. (A) Assays conducted using effector CTLs
specific for the TAP-dependent RRR/B27 and IED/B40
epitopes and the TAP-positive SVK epithelial cell line as a
target. (B) Assays conducted using effector CTLs specific
for the TAP-independent CLG/A2 and LLW/A2 epitopes
and the TAP-positive SVK cell line as a target. (C) Assays
conducted using effector CTLs specific for the TAP-inde-
pendent CLG/A2 and TYG/A24 epitopes and the TAP-
negative C-33A epithelial cell line as a target. All assays
were conducted essentially as in Fig. 4, where necessary
providing the HLA-restriction element by vB27 and vA24,
but in the assays of CLG/A2 epitope presentation included
targets infected with a leader plus epitope minigene con-
struct (vL CLG) and in all assays included a parallel set of
targets prepared from cells exposed to lactacystin for 1 h
immediately before the time of vaccinia infection. Results
are expressed as in Fig. 2 from assays using effector:target
ratios of 8:1 (black bar) and 4:1 (shaded bar).1060 Proteasome-dependent, TAP-independent Processing
were presented efficiently in TAP-negative C-33A cells in-
fected with vLMP2 or coinfected with vLMP2/vA24,
there was again no significant lysis of target cells infected in
the presence of lactacystin.
The possibility that lactacystin might be blocking the
presentation of LMP2-derived epitopes through some
mechanism other than proteasomal inhibition led us to
conduct two additional sets of experiment. In the first case,
we constructed a recombinant vaccinia vL CLG carrying
a leader sequence-positive CLG minigene targeting the
CLG epitope peptide directly to the ER. As shown both
for SVK (Fig. 5 B) and C33-A (Fig. 5 C) targets, infection
with the vL CLG construct sensitized cells to CTL recog-
nition whether or not they had been preexposed to lacta-
cystin, thereby confirming that the drug did not block the
presentation of a proteasome-independent epitope. Sec-
ondly, we repeated the assays with a different proteasome
inhibitor, epoxomicin (34), and again observed that presen-
tation of both the TAP-dependent and TAP-independent
epitopes from LMP2 was blocked by pretreatment of target
cells with the inhibitor (data not shown). These studies
strongly suggest that both TAP-dependent and TAP-inde-
pendent epitopes within LMP2 require the proteasome for
their generation.
LMP2 Epitope Hydrophobicity and TAP-dependence of Pre-
sentation from Minigene Constructs. In view of the above
results, we considered other possible explanations for the
observed differences between LMP2 epitopes in their TAP
dependence. In that context, Table I lists the epitopes ac-
cording to their predicted degree of hydrophobicity (42),
from which it is clear that the five most hydrophobic
epitopes are also those which are TAP independent. This
immediately suggested some form of selective accessing of
the ER by hydrophobic sequences.
To investigate the ability of cytosolically expressed
epitope peptides to access the HLA class I presentation
pathway in TAP-positive and TAP-negative cell back-
grounds, we generated minigene constructs in vaccinia
vectors encoding two representative TAP-independent
epitopes, CLG and TYG, and two representative TAP-
dependent epitopes, IED and RRR, in these cases with-
out leader sequences. Fig. 6 presents the results of cytotox-
icity assays in which a standard TAP-positive LCL and
TAP-negative T2 cells were each infected across a range
of mois with epitope-encoding vaccinia recombinants,
where necessary providing the relevant HLA restriction
element to T2 cells via a second vaccinia recombinant. In
the standard TAP-positive LCL background, all four
minigene constructs sensitized target cells for epitope-spe-
cific lysis in a titratable fashion (Fig. 6 A). By contrast, in
the TAP-negative T2 cell background, both the TYG-
and the CLG-encoding constructs mediated clear CTL
recognition whereas the IED- and the RRR-encoding
constructs did not (Fig. 6 B). As a positive control T2
cells, where necessary infected with the relevant vHLA re-
combinant, were in all cases well recognized after exoge-
nous loading of the epitope peptide. Therefore, the two
epitopes which were known to be presented from endog-
enously expressed LMP2 in a TAP-independent manner
also displayed a TAP-independent phenotype when ex-
pressed in the cytosol from minigenes; this strongly impli-
cates the hydrophobic nature of these epitopes as one de-
terminant of their ability to cross the ER membrane and
bypass the TAP transporter.
Hydrophobic LMP2 Epitopes Remain TAP Independent when
Inserted into a Nuclear Protein. The next set of experiments
sought to determine whether the TAP-independent pre-
sentation of epitopes from endogenously expressed LMP2
required not only intrinsic hydrophobicity of the epitope
sequences but also their location within a native membrane
protein. For this purpose we generated chimaeric con-
structs in which the TAP-independent CLG/A2 and
TYG/A24 epitope sequences were introduced at residue
93 (CLG-N, TYG-N) or at residue 379 (CLG-E, TYG-E)
of BMLF1, a 438 aa EBV nuclear protein of the early lytic
cycle. After recombinant vaccinia construction, vectored
expression of the chimaeric BMLF1 proteins was in each
case confirmed by Western blot analysis and was localized
to the nucleus by immunofluorescence staining; these pat-
terns of expression were indistinguishable from that shown
by a vaccinia recombinant vBMLF1 expressing the wild-
type BMLF1 protein (data not shown). Target cells in-
fected with the chimaeric antigen-encoding viruses, with
vBMLF1 or with vLMP2 were then assayed for recogni-
tion by CLG- and TYG-specific effector CTL clones. The
results of such assays are illustrated in Fig. 7, and follow the
same consistent pattern for both epitopes. Assays conducted
in a TAP-positive LCL expressing both the A*0201 and
the A*2402 allele (Fig. 7 A) clearly confirmed that the
BMLF1 chimaeric constructs could be processed to gener-
ate the relevant inserted epitopes. Thus CLG-specific effec-
tors recognized TAP-positive LCL cells either expressing
LMP2 as the source antigen or expressing the relevant chi-
maeric proteins, BMLF1/CLG-N and BMLF1 CLG-E.
Likewise the TYG-specific effectors specifically recognized
both BMLF1 TYG chimeras as well as LMP2. Surpris-
ingly, we obtained exactly the same series of results when
the assays were conducted in the T2 cell background (Fig.
Table I. LMP2 Epitopes
Epitope HLA restriction Hydrophobicity TAP statusa
LLWTLVVLL A*0201 8.14 Independent
WTLVLLI B*63 6.95 Independent
PYLFWLAAI A*23 6.49 Independent
TYGPFMCL A*2402 5.47 Independent
CLGGLLTMV A*0201 4.14 Independent
IEDPPFNSL B*4001  0.59 Dependent
RRRWRRLTV B*2704  0.60 Dependent
SSCSSCPLSK A*1101  2.35 Dependent
aTAP status as defined by the ability of the epitope to be generated from
endogenously expressed LMP2 in TAP-negative cell backgrounds.1061 Lautscham et al.
7 B). Again the CLG- and TYG-effectors were clearly ca-
pable of recognizing T2 cells expressing their cognate
epitope within a chimaeric nuclear protein at levels at least
as high as those seen with targets expressing the native
LMP2 protein. The TAP-independent phenotype of these
epitopes is therefore apparent even when the source anti-
gen is not a membrane-associated protein.
Hydrophobicity and TAP Independence of Native Epitopes
within Nuclear Proteins. Therefore, we calculated the rela-
tive hydrophobicity of several already defined CTL
epitopes lying within EBV-coded nuclear proteins. Table
II lists seven such epitopes, their antigen of origin, their re-
striction element, and their hydrophobicity. From these we
selected three epitopes for minigene experiments, GLC
(A*0201-restricted) whose hydrophobicity score of 4.41
was similar to the TAP-independent LMP2 epitope CLG,
YPL (B*3501-restricted) whose score of –0.66 was similar
to the TAP-dependent LMP2 epitopes IED and RRR,
and TLD (A*0201-restricted) whose score of 1.72 was in-
termediate between the two extremes. Recombinant vac-
cinias carrying these epitope sequences as minigenes
(vGLC, vYPL, vTLD) were used to infect both TAP-posi-
tive and TAP-negative target cells in CTL-detection assays.
The results are illustrated in Fig. 8. All these minigene con-
structs were capable of sensitizing TAP-positive cells to
recognition in a titratable manner across a range of mois
(Fig. 8 A). However, only the more hydrophobic epitopes
GLC/A2 and TLD/A2 were presented in T2 cells (Fig. 8
B); in contrast the more hydrophilic YPL/B35 epitope was
not presented either in T2 cells expressing HLA B35 from
a vaccinia vector (Fig. 8 B) or in a stable HLA B*3501-
transfectant of T2 (data not shown).
Then, we sought to determine the TAP dependence of
all seven EBV epitopes listed in Table II when expressed in
their native viral antigen. In this case all four of the more
hydrophilic epitopes (FRK/B27, HPV/B35, YPL/B35,
and HRC/B27) proved to be TAP dependent. Represen-
tative data are shown for one such epitope, YPL/B35.
Figure 6. Results of cytotoxicity assays using
vaccinia-minigene constructs in (A) a standard
TAP-positive LCL background with the appropri-
ate HLA-restricting element and (B) T2 cells. Tar-
gets were infected with vTK  as a control or with
vaccinia-minigene recombinants expressing the
TAP-independent CLG/A2 or TYG/A24 epitopes
(vCLG, vTYG) or the TAP-dependent IED/B40
or RRR/B27 epitopes (vIED, vRRR); the mini-
gene recombinants were used across a range of mois
from 10:1 to 0.1:1 as indicated. Target cells ex-
posed to the epitope peptide or to an equivalent
concentration of DMSO solvent served as positive
and negative controls. *Note that in the case of T2
targets, where necessary the relevant HLA restrict-
ing determinant was provided by coinfection with
vA24, vB40, or vB27. Results are expressed as in
Fig. 2 from assays using epitope-specific CTLs at
effector:target ratios of 4:1 (black bar) and 2:1
(shaded bar).1062 Proteasome-dependent, TAP-independent Processing
Thus a YPL epitope-specific CTL clone clearly recognized
TAP-positive target cells expressing the relevant YPL-con-
taining nuclear antigen EBNA3A (Fig. 9 A, bottom)
whereas there was no significant lysis of vEBNA3A-
infected T2 cells whether the HLA B35 restricting deter-
minant was supplied by stable transfection (data not shown)
or by vB35 coinfection (Fig. 9 B, bottom); however, the
B35 molecule was clearly expressed since exogenous load-
ing of vB35-infected T2 targets with the YPL-epitope-
peptide mediated strong lysis by CTLs. Parallel assays using
Figure 7. Processing of chimaeric
BMLF1 proteins for recognition of inserted
epitopes. Results of assays using vaccinia
constructs encoding chimaeric proteins in
which the TAP-independent CLG/A2 and
TYG/A24 epitope sequences from LMP2
were introduced into the BMLF1 nuclear
antigen at one of two locations (CLG-N,
TYG-N inserted at residue 93; CLG-E,
TYG-E inserted at residue 379). Assays
were conducted in (A) a standard TAP-pos-
itive LCL naturally expressing the A2 and
A24 restriction elements and (B) T2 cells
naturally expressing A2 and infected with
vA24. Target cells were infected with
vLMP2, with vBMLF1, or with chimaeric
antigen-encoding vaccinias (vBMLF1-
CLG-N, vBMLF1-CLG-E, vBMLF1-
TYG-N, vBMLF1-TYG-E). Target cells
preexposed to the epitope peptide or to an
equivalent concentration of DMSO solvent
served as positive and negative controls.
Results are expressed as in Fig. 2 from assays
using CLG/A2- or TYG/A24-specific CTL
at effector:target ratios of 4:1 (black bar) and
2:1 (shaded bar).
Table II. Epitopes from EBV-encoded Nuclear Antigens
Antigen Epitope HLA restriction Hydrophobicity TAP statusa
BRLF1 YVLDHLIVV A*0201 6.14 Independent
BMLF1 GLCTLVAML A*0201 4.41 Independent
BMRF1 TLDYKPLSV A*0201 1.72 Dependentb
EBNA3C FRKAQIQGL B*2705 0.24 Dependent
EBNA1 HPVGAEDYFEY B*3501 0.22 Dependent
EBNA3A YPLHEQHGM B*3501  0.66 Dependent
EBNA3B HRCQAIRKK B*2705  2.35 Dependent
aTAP status as defined by ability of the epitope to be generated from endogenously expressed antigen in the TAP-negative T2 cell background.
bNote that the TLD epitope is TAP dependent by these criteria although this epitope is presented in TAP-negative T2 cells when expressed from a
minigene construct (see Figs. 8 and 9).1063 Lautscham et al.
CTLs specific for the relatively hydrophilic FRK/B27,
HRC/B27, and HPV/B35 epitopes from EBNA3C,
EBNA3B, and EBNA1, respectively, gave similar results
(data not shown).
Fig. 9 (top three panels) presents the corresponding data
from experiments with CTL effectors specific for three
A*0201-restricted epitopes of different hydrophobicities de-
rived from EBV nuclear antigens of the lytic cycle. All three
epitopes were presented from their source antigen in TAP-
positive cells (Fig. 9 A). On testing in TAP-negative cells
we found that the least hydrophobic epitope TLD/A2, al-
though capable of TAP-independent presentation when ex-
pressed from a minigene, was nevertheless TAP-dependent
in assays requiring presentation from its native antigen
BMRF1 (Fig. 9 B). By contrast, we observed significant
presentation of the more hydrophobic YVL/A2 and GLC/
A2 epitopes when their native nuclear antigens, BRLF1 and
BMLF1, respectively, were expressed from vaccinia con-
structs in T2 cells (Fig. 9 B). Although levels of lysis of
vBRLF1- and vBMLF1-infected targets were always lower
in the T2 cell background than a standard TAP-positive
LCL, they were nevertheless reproducibly observed on five
successive assays of this kind at levels  20%, compared with
 3% for T2 targets infected with the control vaccinia con-
structs. TAP-independent presentation of the native GLC
epitope was also observed from all four BMLF1/epitope
chimaeric constructs described previously (data not shown).
This indicates that, if sufficiently hydrophobic in sequence,
epitopes native to nonmembrane-associated proteins can be
presented in a TAP-independent manner.
Figure 8. Results of cytotoxicity assays
using vaccinia-minigene constructs in (A) a
standard TAP-positive LCL background
with the appropriate A2 and B35 restriction
elements and (B) T2 cells. Targets were in-
fected with vTK  as a control or with
minigene recombinants expressing the
GLC/A2, TLD/A2, or YPL/B35 epitope
(vGLC, vTLD, vYPL) across a range of
mois as in Fig. 6. Target cells preexposed to
the epitope peptide or to an equivalent con-
centration of DMSO solvent served as posi-
tive and negative controls. *Note that in the
case of T2 targets tested with YPL/B35-
specific effectors, the cells were coinfected
with vB35 to provide the relevant HLA re-
stricting allele. Results are expressed as in
Fig. 2 using epitope specific CTLs at efffec-
tor:target ratios of 4:1 (black bar) and 2:1
(shaded bar).1064 Proteasome-dependent, TAP-independent Processing
Discussion
Apart from early work in the TAP2 mutant mouse line
RMA-S where findings were complicated by a suggestion
of residual TAP function (43), published examples of TAP-
independent presentation from endogenously expressed an-
tigens all involve epitopes derived from secreted proteins or
from integral membrane proteins with ectodomains which
naturally access the ER. All such TAP-independent
epitopes appear to be generated either from signal se-
quences liberated by the signal peptidase enzyme (10, 15,
16) or from breakdown from within the secretory pathway
by other ER-resident or Golgi-resident proteases (17–20).
By contrast the LMP2 protein represents a source antigen
which contains at least some TAP-independent epitopes
yet which has no conventional signal sequence and no sig-
nificant projection into the ER. Indeed to our knowledge
LMP2 is the only such multiple membrane spanning struc-
ture to be analyzed as a CTL target. Our studies, conducted
in both lymphoid and epithelial target cell backgrounds and
involving an extended range of LMP2 epitopes, clearly
identify a subset of epitopes which are consistently TAP in-
dependent (Figs. 2–5). Furthermore this TAP-independent
processing is observable when LMP2 is expressed at physi-
ological levels and not just at the enhanced levels seen from
vaccinia viral vectors. Thus, clones specific for the TAP-
independent CLG/A2 epitope show significant baseline kill-
ing of unmanipulated T2 cells (Fig. 2 D), consistent with
the fact that the T2 line is A*0201 positive and expresses
low levels of LMP2 from its endogenous EBV genome.
Furthermore, an individual with an inactivating mutation
in the TAP2 gene was capable of mounting LMP2-specific
CTL responses after natural EBV infection in vivo (23),
and CTL clones derived from this individual allowed us to
Figure 9. Processing of EBV nuclear an-
tigens BRLF1, BMLF1, BMRF1, and
EBNA3A for recognition of native
epitopes. Results of assays using native nu-
clear antigen-encoding vaccinia constructs
in (A) a standard TAP-positive LCL with
the appropriate A2 and B35 restriction ele-
ments and (B) in T2 cells. Targets were ei-
ther infected with recombinant vaccinias
encoding the native antigens vBMLF1,
vBMRF1, vBRLF1, vEBNA3A (with
vLMP2 and vEBNA3C as controls), or pre-
exposed to their epitope peptides GLC,
TLD, YVL, YPL (with CLG and FRK as
controls). *Note that in the case of T2 tar-
gets tested with YPL/B35-specific effectors,
the cells were coinfected with vB35 to pro-
vide the relevant HLA restricting allele. Re-
sults are expressed as in Fig. 2 using epitope
specific CTLs at effector:target ratios of 4:1
(black bar) and 2:1 (shaded bar).1065 Lautscham et al.
map a new TAP-independent LMP2 epitope, WTL/B63;
such clones again showed significant baseline killing of
TAP-negative LCL cells expressing physiological levels of
LMP2 and HLA B*63 (Fig. 3).
Our first objective was to determine whether there was
any relationship between epitope location in the native
LMP2 protein and TAP dependence. One possible sce-
nario, originally influenced by models of membrane pro-
tein breakdown (44, 45), was that LMP2 might be cleaved
on its cytosolic face, possibly by a nonproteasomal mecha-
nism, and particular transmembrane/lumenal loop frag-
ments released directly into the ER, thereby allowing some
epitopes to access HLA class I molecules via a TAP-inde-
pendent route (21). Contrary to such a model, however,
we found that one epitope naturally lying on a lumenal
loop (IED/B40) was TAP dependent whereas one of the
epitopes predominantly situated on a cytosolic loop (TYG/
A24) was TAP independent. Furthermore, the processing
of TAP-independent epitopes from LMP2 showed the
same sensitivity to two proteasomal inhibitors, lactacystin
(33, 46), and epoxomicin (34), as seen for conventional
TAP-dependent epitopes. These compounds are among
the most specific of the known proteasome inhibitors,
functioning via covalent linkage to particular catalytic sub-
units of the proteasome (33, 46). Although widely used in
antigen processing experiments to demonstrate involve-
ment of the proteasome (12, 13, 47), lactacystin also has
some inhibitory effects on cathepsin A (48), but these are
reversible and would therefore not be effective under the
conditions of lactacystin pulsing used in the present ex-
periments. Likewise lactacystin has been reported to show
partial inhibition of tripetidyl-peptidase-II (TPPII) (49), a
cytosolic protease which can substitute for proteasome-
mediated general protein turnover in certain circumstances
and may substitute, albeit inefficiently, for the proteasome’s
antigen processing function (49, 50). However, the con-
centration of lactacystin used in the present work had little
effect on protein turnover in cells where TPPII activity is
dominant whereas turnover was strongly inhibited in cells
with regular proteasome function (51).
From the above we infer that, unlike all other published
TAP-independent epitopes within endogenously expressed
proteins (10, 16), those within LMP2 are dependent upon
the proteasome for their generation. The processing of
LMP2 might occur either in its membrane location (since
membrane associated proteasomes have been detected in
several systems; references 52–54) or possibly as a recently
synthesized but misfolded polypeptide marked for degrada-
tion in the cytosol (55, 56). LMP2 has been reported to
bind Nedd4-like ubiquitin-ligases through PPPY motifs in
the cytosolic NH2-terminal domain, thereby producing a
ubiquitination signal which could target LMP2-associated
src kinases or even LMP2 itself to the proteasome (57, 58).
However, this interaction is not required in the present
context since a naturally expressed version of LMP2 lack-
ing the NH2-terminal domain (so called LMP2B) is pro-
cessed to TAP-dependent and TAP-independent epitopes
as effectively as the full-length protein (reference 21 and
unpublished data).
Insights into the mechanism of TAP-independent
epitope presentation came from experiments expressing
LMP2 epitopes as cytosolic peptides from vaccinia mini-
gene constructs. This produced the same clear discrimi-
nation between TAP-dependent and TAP-independent
epitopes as observed with LMP2 processing itself (Fig. 6),
implying that TAP independence was a feature of the
epitope sequence per se. An apparently strong correlation
between TAP-independence and LMP2 epitope hydro-
phobicity (Table 1) led us to construct minigenes encoding
epitopes native to nonmembrane associated proteins but
with hydrophobicity indices (GLC/A2, 4.41; TLD/A2,
1.72; YPL/B35,  0.6) which spanned the same range as
the LMP2 epitopes. Again the two most hydrophobic
epitopes GLC/A2 and TLD/A2 were clearly TAP-inde-
pendent when expressed as cytosolic peptides whereas the
hydrophilic YPL/B35 epitope was not (Fig. 8). Other
studies expressing epitope minigenes either from plasmid or
vaccinia viral vectors have reported discrimination between
different epitopes in their ability to be presented in TAP-
negative cells (59, 60). Close inspection of the epitopes in
one such study (60) indicates that the three TAP-indepen-
dent sequences had hydrophobicities of 1.44 to 2.63, com-
pared with a TAP-dependent epitope hydrophobicity of
 3.68. In another earlier study where the data was inter-
preted as showing no such correlation (59), recalculation of
hydrophobicities in fact confirm the relationship between
TAP-independence, and hydrophobicity scores for 9 of the
10 peptide sequences examined, the exception being a 12-
mer peptide which did not represent the minimal epitope
sequence. We infer that hydrophobicity is indeed an im-
portant determinant of the TAP-independent status of
epitope sequences, at least when expressed from minigenes.
Finally, our experiments showed that the TAP-inde-
pendent presentation of hydrophobic epitopes from en-
dogenously expressed antigen does not require the source
antigen to be a membrane-associated protein. Thus trans-
fer of the CLG/A2 and TYG/A24 epitope sequences into
an EBV nuclear antigen BMLF1 still allowed their efficient
presentation in T2 cells (Fig. 7). Furthermore two equally
hydrophobic epitope sequences (GLC/A2 and YVL/A2),
native to BMLF1 and to another EBV nuclear antigen
BRLF1 respectively, were also presented from their vac-
cinia-expressed native antigen via a TAP-independent
route (Fig. 9). Given an apparent discrepancy between the
above BMLF1 result and that seen in earlier work (21), we
rechecked BMLF1 processing in several different HLA
class I–transfected subclones of T2 as well as in different
passages of T2 itself. All showed clear presentation of the
GLC/A2 epitope with the single exception of the T2:
B*2705 transfectant, the target line used in our original
study (data not shown); why T2:B27.05 cells give atypical
results in BMLF1 processing assays is unclear but appears
to reflect a peculiarity of this transfectant. Throughout
these experiments on GLC/A2 and YVL/A2 processing,
epitope-specific recognition in T2 cell backgrounds was
 50% that seen for the same constructs in TAP-positive1066 Proteasome-dependent, TAP-independent Processing
LCL cells. However, this appears to reflect a less efficient
generation of these epitopes by proteolysis in the immu-
noproteasome-negative T2 environment (rather than less
efficient epitope transport) since the same comparatively
low levels of lysis vis-à-vis that seen in LCL cells were also
observed in the TAP-transfected T3 reference line (data
not shown). However, we did note a clear difference be-
tween the results of minigene assays and of native antigen
processing assays with the TLD/A2 epitope from another
EBV nuclear antigen, BMRF1. This epitope, with an in-
termediate hydrophobicity of 1.72, was TAP-independent
as a minigene-encoded peptide but TAP-dependent when
expressed within its native protein (Figs. 8 and 9), results
which mirror the data obtained by Norbury et al. (60) us-
ing epitopes with hydrophobicities in the 1.44–2.63 range.
This reemphasizes the fact that vaccinia minigene con-
structs produce much larger numbers of cytosolic epitope
peptides than are generated from processing of a vaccinia-
encoded antigen (61), and such quantitative differences
can become particularly important determinants of epitope
representation at the T2 cell surface when epitope hydro-
phobicity is itself suboptimal.
Therefore, this study highlights the existence of a protea-
some-dependent, TAP-independent pathway of epitope
processing/presentation which appears to be restricted to
highly hydrophobic epitopes that can be drawn either from
membrane-associated or from nonmembrane-associated
proteins. The pathway of TAP-independent access into
the ER remains to be determined. One possible route
could involve the ER translocon Sec61p, since this is in-
volved not only in the recognition of hydrophobic signal
sequences for protein translocation into the ER but also
in the retrograde transport of peptides from the ER back
into the cytosol (62). Another possibility would be the
postulated transporter whose existence was inferred from
studies of TAP-independent presentation of epitopes
from chimaeric Jaw-1 constructs (18); however, there is
no evidence that such a transporter would have selectiv-
ity for hydrophobic sequences. Alternatively it may be
that hydrophobicity allows peptides to penetrate mem-
branes by an energy-independent mechanism rather than
via a specific transporter pathway. Indeed this is sup-
ported by earlier findings of an ATP-independent trans-
port into microsomes which was selective for 2 of 3
epitope peptides (63) and where inspection of sequences
clearly shows a correlation between transport and hydro-
phobicity indices.
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